Next step in the development of mesoprogestins: the preclinical profile of EC313

INTRODUCTION: The pharmacological target for progesterone, different progestins, and Selective Progesterone Receptor Modulators (SPRMs) is the nuclear progesterone receptor (PR). EC313 is a new member of a subgroup of SPRMs, mesoprogestins, which combine especially PR- agonistic and PR-antagonistic...

Descripción completa

Detalles Bibliográficos
Autores principales: Błaszczak-Świątkiewicz, K., Krupa, A., Mnich, E., Elger, W., Oettel, M., Nair, H., Wierzbicki, M., Sieroszewski, P., Shaked, Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520499/
https://www.ncbi.nlm.nih.gov/pubmed/37766684
http://dx.doi.org/10.3389/fendo.2023.1201547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520499/
https://www.ncbi.nlm.nih.gov/pubmed/37766684
http://dx.doi.org/10.3389/fendo.2023.1201547

Ejemplares similares